Please use this identifier to cite or link to this item:
|Title:||The global implications of the gentamicin histamine contamination- sorting fact from fiction.|
|Authors:||Trubiano, Jason A;Keith, Claire;Devchand, Misha;Garrett, Kent|
|Affiliation:||Pharmacy Department, Austin Health, Heidelberg, Victoria, Australia|
The National Centre for Infections in Cancer, Department of Infectious Diseases, MacCallum Cancer Centre, Melbourne, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, Victoria, Australia
Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
|Citation:||Antimicrobial agents and chemotherapy 2018; online first: 26 November|
|Abstract:||On the 6th of October 2017 the Therapeutics Goods Administration (TGA) in conjunction with Pfizer Australia released a statement to recall 10 batches of gentamicin Infection BP 80mg in 2ml Steriluer ampoules, due to the finding that these batches may have contained higher than expected amounts of histamine, a residual from the manufacturing process(1).….|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.